This site provides INTERCEPT product information for Health Care Professionals in the United States.

Select Page
READY WHEN YOU ARE

INTERCEPT® Fibrinogen Complex

INTERCEPT Fibrinogen Complex is a pathogen reduced, fibrinogen enriched, blood component for transfusion providing you with an immediate source* of key factors known to be important in effective hemostasis.

Breakthrough Device for Treating Uncontrolled Bleeding

The ready-to-use Fibrinogen Complex* approved specifically for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

  • Pathogen Reduced Cryoprecipitated Fibrinogen Complex (Fibrinogen Complex) is prepared from the INTERCEPT® Blood System for Cryoprecipitation.
  • Immediate, enriched source of key factors in effective hemostasis1-3
      • Fibrinogen
      • Factor XIII
      • von Willebrand Factor (vWF)
      • Other vital clotting proteins
FDA

Transfuse Immediately With The First Blood Components*

Thaw INTERCEPT Fibrinogen Complex in advance to minimize wait times and have available for immediate use.

Improve Efficiencies

Transfusion
Transfusion Ready
  • Thawed in advance
  • Ready to deploy with first blood components
  • No additional labeling or preparation required
Minimize wait times
Minimize Wait Times
  • Immediately available to fulfill order*
  • Improve order-to-transfusion times
  • Single-use hemostatic doses
  • Pre-pooled high doses available**
Reduce waste
Reduce Waste
  • 5-day post-thaw shelf life
  • Return to inventory if not transfused
  • Broad spectrum transfusion transmitted infection (TTI) risk reduction
view all case studies

Pathogen Reduced Cryoprecipitated Fibrinogen Complex is indicated for6:

  • Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
  • Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
  • Second-line therapy for von Willebrand disease (vWD).
  • Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: INTERCEPT Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII

Order Today

Become a Customer

You may also be interested in

Why Blood Safety Matters
Pathogen Reduction: Be Ready.
Reduce the risk of transfusion transmitted infections by using blood products treated with the INTERCEPT Blood System Pathogen Reduction System.
Learn more
Elevate Patient Care
Dosage: Hemorrhage control requires all hands on deck.
Pre-pooled INTERCEPT Fibrinogen Complex facilitates transfusion of high doses of fibrinogen from a single container.
Learn more
Elevate Patient Care
Onboarding: Implement once, streamlined ordering after.
Learn more

* INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.
**Pooling facilitates transfusion of high doses of fibrinogen from a single container. Fibrinogen content of Fibrinogen Complex depends on donor plasma fibrinogen levels.

References:

  1. Levy JH, Welsby I, et al. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014;54(5):1389-1405; quiz 1388.
  2. Schroeder V, Kohler HP. Factor XIII: Structure and Function. Semin Thromb Hemost 2016;42(4):422-428.
  3. Peyvandi, F. Diagnosis and management of patients with von Willebrand’s disease in Italy: an Expert Meeting Report. Blood Transfus 2018;16(4):326-328.
  4. Holcomb JB, Fox EE, Zhang X, et al. Cryoprecipitate Use in the Prospective Observational Multicenter Major Trauma Transfusion study (PROMMTT). The journal of trauma and acute care surgery 2013;75:S31-S9.
  5. AABB. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, MD: AABB; 2024.
  6. INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex Package Insert.